Capricor Therapeutics (CAPR) risk factors, FY2025 10-K

Risks Related to Our Business

1. 01We need additional funding before we can complete the development of our product candidates. If we are unable to obtain such additional capital, we will be forced to delay, reduce or eliminate our product development and clinical programs and may not have the capital required to otherwise operate our businessNew
2. 02From inception, we have financed our operations through private and public sales of our equity securities, government grants and payments from distribution agreements and collaboration partners83% rewritten
3. 03We have a history of net losses, and we expect losses to continue for the foreseeable future. In addition, a number of factors may cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance
4. 04The Company’s cell therapy technology (Deramiocel) is in late-stage development but not yet an approved product, and its exosome technology is still in preclinical development
5. 05Our product candidates may, or in some cases, will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales
6. 06Business disruptions such as natural disasters, widespread infectious diseases, or pandemics or geopolitical conflicts could seriously harm our future revenues and financial condition and increase our costs and expenses
7. 07Tariffs imposed by foreign governments in retaliation for U.S. trade measures could adversely affect our international sales, results of operations, and financial conditionNew
8. 08A breakdown, corruption or breach of our information technology systems or computer systems, or those used or hosted by our CROs, contractors, consultants or third-party vendors could subject us to liability or interrupt the operation of our business
9. 09If we achieve our near-term product development milestones, we may not be able to manage any subsequent growth32% rewritten

Risks Related to Clinical and Commercialization Activities

1. 10Our success depends upon the viability of our product candidates and we cannot be certain any of them will receive regulatory approval to be commercialized25% rewritten
2. 11We have limited experience in conducting late-stage clinical trials, which are complex and subject to strict regulatory oversight66% rewritten
3. 12sufficiently enroll or produce results necessary to support regulatory approval in the United States or elsewhere, or if they show undesirable side effects, we will be unable to commercialize these product candidatesNew
4. 13As the results of earlier preclinical studies or clinical trials are not necessarily predictive of future results, any product candidate we advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval
5. 14Our exosome technologies are based on a novel therapeutic approach which makes it difficult to predict the time and cost of development and the probability of subsequently obtaining regulatory approval, if at all51% rewritten
6. 15believe that there is excessive competition in a disease target. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate or commercializing any product candidates we may develop on a timely or profitable basis, if at allNew
7. 16Negative developments in the field of exosomes could damage public perception of any product candidates that we develop, which could adversely affect our ability to conduct our business or obtain regulatory approvals for such product candidates91% rewritten
8. 17We may not be able to file INDs to commence additional clinical trials on the timelines we expect, and even if we are able to do so, the FDA may not permit us to proceed
9. 18Delays in the commencement, enrollment, and completion of clinical testing, as well as reduced government funding of certain clinical trials, could result in increased costs to us and delay or limit our ability to obtain regulatory approval for our product candidates47% rewritten
10. 19The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities44% rewritten
11. 20there is a relatively limited safety data set for product candidates using an exosome platform. An adverse safety issue or other adverse finding in a clinical trial conducted by a third-party with a product candidate similar to ours could adversely affect our clinical trialsNew
12. 21The regulatory pathway for COVID-19 or other infectious disease vaccines is continually evolving and may result in unexpected or unforeseen challenges
13. 22We may not be successful in our efforts to identify or discover additional potential product candidates or additional indications for our existing product candidates
14. 23Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable compounds for preclinical and clinical development, our business would be harmed
15. 24Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success
16. 25We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do49% rewritten
17. 26The FDA has granted orphan drug status and an RMAT designation to Deramiocel for the treatment of DMD, but we may be unable to maintain or receive the benefits associated with orphan drug status , including market exclusivity, or an RMAT designation
18. 27Even if we were to obtain approval for Deramiocel for the treatment of DMD with the rare pediatric disease designation, the Rare Pediatric Disease Priority Review Voucher Program may no longer be in effect at the time of such approval39% rewritten
19. 28Providing product for use in third-party trials or for compassionate use poses risks to our product candidates
20. 29Our products face a risk of failure due to adverse immunological reactions
21. 30Our business faces significant government regulation, and there is no guarantee that our product candidates will receive regulatory approval55% rewritten
22. 31subject to regulations established by local authorities and local law. Any such determinations would delay or deny the introduction of our product candidates to the market and have a material adverse effect on our business, financial condition, and results of operationsNew
23. 32There are additional risks involved in conducting clinical trials internationally
24. 33Even if our product candidates receive regulatory approval, we may still face future development and FDA regulatory difficulties
25. 34If we or current or future collaborators, manufacturers, or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and substantial penalties, which could affect our ability to develop , market, and sell our products and may harm our reputation
26. 35Any drugs we develop may become subject to unfavorable pricing regulations, third-party coverage, and reimbursement practices or healthcare reform initiatives, thereby harming our future business prospects92% rewritten
27. 36is granted. As a result, we might obtain regulatory approval for a product in a particular country but then be subject to price regulations that delay our commercial launch of the product and negatively impact the revenues we are able to generate from the sale of the product in that countryNew
28. 37Our risk mitigation measures cannot guarantee that we effectively manage all operational risks and that we are in compliance with all potentially applicable U.S. federal and state regulations and all potentially applicable foreign regulations and other requirements
29. 38Our employees and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
30. 39Our ability to obtain reimbursement or funding for our programs from the federal government may be impacted by possible reductions in federal spending60% rewritten
31. 40Vaccines carry unique risks and uncertainties, which could have a negative impact on future results of operations
32. 41Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our future product revenues and materially harm our businessNew
33. 42MFN pricing models in the U.S. could also affect our international commercial strategy, directly and/or through our commercial partners, and future decisions on reimbursement and commercialization in certain jurisdictionsNew

Risks Related to the Manufacturing of our Product Candidates

1. 43We have limited commercial manufacturing experience and our manufacturing facilities may not receive or maintain the regulatory approvals required to support commercializationNew
2. 44The manufacture of cell-based therapies such as Deramiocel is complex, highly regulated and subject to multiple operational and technical risksNew
3. 45We will need to increase our manufacturing capacity in the future and we may encounter problems at our current manufacturing facilities59% rewritten
4. 46We may need to rely exclusively on third parties to formulate and manufacture our product candidates and provide us with the devices and other products necessary to administer such a product
5. 47Disruptions in our supply chain or failure to adequately forecast product demand could result in significant delays or lost sales23% rewritten
6. 48Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties
7. 49The third parties we use in the manufacturing process for our product candidates may fail to comply with cGMP regulations

Risks Related to Our Intellectual Property

1. 50We may face uncertainty and difficulty in obtaining and enforcing our patents and other proprietary rights61% rewritten
2. 51It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If we fail to protect or enforce our intellectual property rights adequately or secure rights to patents of others, the value of our intellectual property rights and product candidates would diminish93% rewritten
3. 52to sell, or importing our products is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these products and activitiesNew
4. 53If any of our trade secrets, know-how or other proprietary information is improperly disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer
5. 54We may incur substantial costs as a result of litigation or other adversarial proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use of, our technology
6. 55We may be subject to claims that we or our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties
7. 56We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business

Risks Related to Our Relationships with Third Parties

1. 57We will depend on our exclusive distributor, Nippon Shinyaku, for the commercial sale of Deramiocel in Duchenne muscular dystrophy (“DMD”) in the United States and Japan, if regulatory approval is obtained in those territories75% rewritten
2. 58If we enter into strategic partnerships, we may be required to relinquish important rights to and control over the development of our product candidates or otherwise be subject to terms unfavorable to us
3. 59Our results of operations could be materially harmed if we or our distributor are unable to accurately forecast customer demand for our products and manage our inventory
4. 60We are dependent on our relationships with our licensors and collaborators and there is no guarantee that such relationships will be maintained or continued
5. 61In addition, we are responsible for the cost of filing and prosecuting certain patent applications and maintaining certain issued patents licensed to us. If we do not meet our obligations under our license agreements in a timely manner, we could lose the rights to the proprietary technology
6. 62Commencing in 2009, we received several grants from the NIH and DoD to fund various projects. Some of these awards remain subject to annual and quarterly reporting requirements and require us to allocate expenses to the applicable project
7. 63We rely and will rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates49% rewritten
8. 64As we advance our programs through potential commercial launch, we have substantial fixed costs associated with third party contracts that will increase and will not be able to be terminated, even if our product candidates are not ultimately approved41% rewritten

Risks Related to Competitive Factors

1. 65Our products will likely face intense competition
2. 66If we do not establish strategic partnerships, we will have to undertake development and commercialization efforts on our own, which would be costly and delay our ability to commercialize any future products or product candidates
3. 67We have no experience selling, marketing, or distributing products and no current internal capability to do so
4. 68If any of our product candidates for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales, if any, will be limited
5. 69Our development of a potential vaccine for COVID-19 or other indications is at an early stage and is subject to significant risks
6. 70Even if our product candidates are approved, our ability to generate product revenues will be diminished if our products sell for inadequate prices or patients are unable to obtain adequate levels of reimbursement50% rewritten

Risks Related to Product and Environmental Liability

1. 71Our products may expose us to potential product liability, and there is no guarantee that we will be able to obtain and maintain adequate insurance to cover these liabilities
2. 72Our business involves risk associated with handling hazardous and other dangerous materials
3. 73Our business depends on compliance with ever-changing environmental and human health and safety laws

Risks Related to Our Common Stock

1. 74We expect that our stock price will continue to fluctuate significantly
2. 75We have never paid dividends and we do not anticipate paying dividends in the future43% rewritten
3. 76We may issue shares of blank check preferred stock without stockholder approval in the future
4. 77Market and economic conditions may adversely affect our industry, business and ability to obtain financing47% rewritten
5. 78If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline
6. 79The operational and other projections and forecasts that we may make from time to time are subject to inherent risks, many of which are beyond our control34% rewritten
7. 80Our certificate of incorporation and by-laws contain provisions that may discourage, delay or prevent a change in our management team that stockholders may consider favorable
8. 81These provisions could make it more difficult for our stockholders to affect our corporate policies or make changes in our Board of Directors and for a third-party to acquire us, even if doing so would benefit our stockholders30% rewritten
9. 82The Company’s ability to utilize Nile’s net operating loss and tax credit carryforwards in the future is subject to substantial limitations and may further be limited as a result of the merger with Capricor
10. 83The requirements of being a public company may strain our resources and divert management’s attention from operating our business
11. 84Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price
12. 85You may experience future dilution as a result of future equity offerings
13. 86If our business plans are unsuccessful, our stockholders could lose all or a substantial portion of their investment in usNew
14. 87Short sellers may engage in market manipulating activities and seek to drive down the market price of our common sharesNew
15. 88We may be at risk of securities class action litigation or litigation initiated by individual stockholders